药群论坛

 找回密码
 立即注册

只需一步,快速开始

查看: 957|回复: 3
打印 上一主题 下一主题

[已解决] 美罗培南三水合物(meropenem trihydrate)BP2017标准

[复制链接]
跳转到指定楼层
楼主
zwindy16 发表于 2017-5-31 14:05:32 | 只看该作者 回帖奖励 |倒序浏览 |阅读模式
求助版块
文献题目: 美罗培南三水合物(meropenem trihydrate)BP2017标准
作者: BP
期刊名:
期刊年份: 2017
文献链接:

马上注册,结交更多好友,享用更多功能,让你轻松玩转社区

您需要 登录 才可以下载或查看,没有帐号?立即注册  

x
谁有美罗培南三水合物(meropenem trihydrate)BP2017标准,请帮提供一份,谢谢!
回复

使用道具 举报

沙发
 楼主| zwindy16 发表于 2017-5-31 17:03:22 | 只看该作者
希望得到各位老师帮助,必有重谢!
回复 支持 反对

使用道具 举报

板凳
yf09 发表于 2017-6-1 15:55:20 | 只看该作者
本帖最后由 yf09 于 2017-6-1 03:56 PM 编辑

meropenem trihydrate-BP2017
Updated Ph. Eur. 9.0, effective 01/01/2017
Maximise
Meropenem Trihydrate
General Notices

(Ph. Eur. monograph 2234)
C17H25N3O5S,3H2O  437.5 119478-56-7 
Action and use
Carbapenem antibacterial.

Ph Eur

DEFINITION
(4R,5S,6S)-3-[[(3S,5S)-5-[(Dimethylamino)carbonyl]pyrrolidin-3-yl]sulfanyl]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid trihydrate.

Semi-synthetic product derived from a fermentation product, or synthetic product.

Content
97.5 per cent to 102.0 per cent (anhydrous substance).

CHARACTERS
Appearance
White or light yellow, crystalline powder.

Solubility
Sparingly soluble in water, practically insoluble in ethanol (96 per cent) and in methylene chloride.

IDENTIFICATION
Infrared absorption spectrophotometry (2.2.24).

Comparisonmeropenem trihydrate CRS.

TESTS
Appearance of solution
The solution is clear (2.2.1) and not more intensely coloured than reference solution Y5 (2.2.2, Method II).

Dissolve 1.0 g in 20 mL of a 50 g/L solution of sodium hydrogen carbonate R.

pH (2.2.3)
4.0 to 6.0.

Dissolve 0.20 g in carbon dioxide-free water R and dilute to 20 mL with the same solvent.

Specific optical rotation (2.2.7)
-21 to -17 (anhydrous substance).

Dissolve 0.125 g in water R and dilute to 25.0 mL with the same solvent.

Related substances
Liquid chromatography (2.2.29). Prepare test solutions (a) and (b) and reference solution (c) immediately before use. Prepare and store reference solution (a) at 4 °C and use within 6 h.

Solvent mixture To 1.0 mL of triethylamine R add 900 mL of water for chromatography R. Adjust to pH 5.0 with dilute phosphoric acid R and dilute to 1000.0 mL with water for chromatography R.

Test solution (a) Dissolve 0.100 g of the substance to be examined in the solvent mixture and dilute to 25.0 mL with the solvent mixture.

Test solution (b) Dissolve 50.0 mg of the substance to be examined in the mobile phase and dilute to 100.0 mL with the mobile phase.

Reference solution (a) Dilute 1.0 mL of test solution (a) to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.

Reference solution (b) In order to prepare impurities A and B in-situ, heat 10 mL of test solution (a) to 60 °C for about 20 min or, alternatively, allow 10 mL of test solution (a) to stand at room temperature for about 8 h.

Reference solution (c) Dissolve 50.0 mg of meropenem trihydrate CRS in the mobile phase and dilute to 100.0 mL with the mobile phase.

Column:
— size: l = 0.25 m, Ø = 4.6 mm;
— stationary phase: base-deactivated end-capped octadecylsilyl silica gel for chromatography R (5 μm);
— temperature: 40 °C.
Mobile phaseacetonitrile R1, solvent mixture (7:100 V/V).

Flow rate 1.6 mL/min.

Detection Spectrophotometer at 220 nm.

Injection 10 μL of test solution (a) and reference solutions (a) and (b).

Run time 4 times the retention time of meropenem.

Relative retention With reference to meropenem (retention time = about 7 min): impurity A = about 0.5; impurity B = about 2.2.

System suitability: reference solution (b):
— resolution: minimum 5.0 between the peaks due to impurity A and meropenem.
Limits:
— correction factor: for the calculation of content, multiply the peak area of impurity A by 1.6;
— impurity A: not more than 5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.5 per cent);
— impurity B: not more than 3 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.3 per cent);
— unspecified impurities: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.10 per cent);
— sum of impurities other than A and B: not more than 3 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.3 per cent);
— disregard limit: 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent).
For meropenem trihydrate produced by a fully synthetic process:
— unspecified impurities: for each impurity, not more than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent);
— disregard limit: 0.3 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.03 per cent).
Water (2.5.12)
11.4 per cent to 13.4 per cent, determined on 0.100 g.

Sulfated ash (2.4.14)
Maximum 0.1 per cent, determined on 1.0 g.

Bacterial endotoxins (2.6.14)
Less than 0.125 IU/mg, if intended for use in the manufacture of parenteral preparations without a further appropriate procedure for the removal of bacterial endotoxins.

ASSAY
Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.

Injection Test solution (b) and reference solution (c).

Calculate the percentage content of C17H25N3O5S taking into account the assigned content of meropenem trihydrate CRS.

STORAGE
If the substance is sterile, store in a sterile, airtight, tamper-proof container.

LABELLING
The label states, where applicable, that the substance is suitable for use in the manufacture of parenteral preparations.

IMPURITIES
Specified impurities A, B

A. (4R,5S)-5-[(1S,2R)-1-carboxy-2-hydroxypropyl]-3-[[(3S,5S)-5-[(dimethylamino)carbonyl]pyrrolidin-3-yl]sulfanyl]-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid,
B. (4R,5S,6S)-3-[[(3S,5S)-1-[(2S,3R)-2-[(2S,3R)-5-carboxy-4-[[(3S,5S)-5-[(dimethylamino)carbonyl]pyrrolidin-3-yl]sulfanyl]-3-methyl-2,3-dihydro-1H-pyrrol-2-yl]-3-hydroxybutanoyl]-5-[(dimethylamino)carbonyl]pyrrolidin-3-yl]sulfanyl]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid.
Ph Eur


回复 支持 反对

使用道具 举报

地板
 楼主| zwindy16 发表于 2017-6-2 08:42:05 | 只看该作者
非常非常感谢!
回复 支持 反对

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册  

本版积分规则

QQ|手机版|药群论坛 ( 蜀ICP备15007902号 )

GMT+8, 2024-6-7 01:06 PM , Processed in 0.100586 second(s), 19 queries .

本论坛拒绝任何人以任何形式在本论坛发表与中华人民共和国法律相抵触的言论! X3.2

© 2011-2014 免责声明:药群网所有内容仅代表发表者个人观点,不代表本论坛立场。

快速回复 返回顶部 返回列表